General (512) Financials (83) Partnerships (64) New Products (32) Acquisitions (22) New Technologies (10) Ad hoc (8)
Corporate (148) Cell & Gene Technologies and Bioscience (113) Discontinued businesses (104) Biologics (101) Capsules & Health Ingredients (61) Pharma and Biotech (36) Small Molecules (26) Site News (7)
2022 (23) 2021 (64) 2020 (84) 2019 (101) 2018 (91) 2017 (80) 2016 (75) 2015 (58) 2014 (62)
Showing 1‐20 of 500
results per page
09 May 2022
Lonza and ALSA Ventures Collaborate to Provide Development and Manufacturing Services for Biotech Firms
Lonza to support ALSA Ventures’ portfolio companies with services supporting de-risking, early development and manufacturing of next-generation modalities ALSA Ventures to...
09 May 2022
Lonza Expands its Capsugel® Capsule Offering to Include Titanium Dioxide-Free White Hard Gelatin Capsules
New hard gelatin capsule provides a bright white color, while meeting titanium dioxide-free requirements for foods in the European Union The new capsule features an...
05 May 2022
Lonza gibt Ergebnisse der Generalversammlung 2022 bekannt – Alle Anträge des Verwaltungsrats wurden angenommen
Die Aktionäre wählten alle zur Wiederwahl stehenden Mitglieder des derzeitigen Verwaltungsrats wieder, und wählten Marion Helmes und Roger Nitsch als neue Mitglieder des...
05 May 2022
Lonza Announces Results of the 2022 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of...
29 Apr 2022
Lonza to Divest its Quakertown Site Specialized in Particle Size Reduction; Business to be Renamed Microsize
Agreement for the sale of Lonza site in Quakertown, PA (US)
25 Apr 2022
Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation The complementary...
25 Apr 2022
Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using Lonza’s GS Xceed® Gene Expression System
Luzhu Biotech entered a licensing agreement to use Lonza’s GS Xceed® Gene Expression System with GS piggyBac® transposon technology Luzhu Biotech is developing a recombinant...
07 Apr 2022
Lonza and Asher Biotherapeutics to Collaborate on Manufacturing AB359, a Cis-Targeted IL-2 Immunotherapy
Lonza to provide drug substance manufacturing for Asher Bio’s molecule, AB359, a cis-targeted IL-2 immunotherapy Drug substance manufacturing to be carried out at Lonza’s...
04 Apr 2022
Lonza Expands the Functionality of Cocoon Platform by Implementing Magnetic Cell Selection
Lonza has expanded the Cocoon® Platform functionality by releasing the second-generation instrument, including new integrated capabilities in cell binding, cell separation,...
31 Mar 2022
Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products
Lonza joins IPAC-RS,  the leading global voice of the orally inhaled and nasal drug products industry and committed to advancing science-based regulatory approaches...
24 Mar 2022
Lonza Publishes Invitation to the 2022 Annual General Meeting and 2021 Annual and Sustainability Reports
Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of...
23 Mar 2022
Christian Seufert appointed as President of Capsules and Health Ingredients Division
Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a...
21 Mar 2022
Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply The collaboration is projected to take Cantrixil through the planned Phase II...
15 Mar 2022
Lonza is among the 2022 World's Most Ethical Companies, as recognized by Ethisphere
Award honors Lonza for demonstrating strong commitment to business integrity through best-in-class ethics, compliance and governance practices   Lonza is one of only three...
08 Mar 2022
Lonza Expands API Development and Manufacturing Laboratories in Nansha, China
The development and cGMP manufacturing laboratories will support the global operations network and provide additional early-phase highly-potent API manufacturing capabilities...
07 Mar 2022
Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development
Lonza now offers human cord blood CD34+ hematopoietic stem cells in large batch sizes, leading the way in addressing a critical unmet market need CD34+ cell lots in a range...
27 Jan 2022
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN)...
26 Jan 2022
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1   CHF 1.7 Milliarden Kern-EBITDA resultieren in einer Marge von 30,8%  2021...
26 Jan 2022
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth  CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8%  2021 CAPEX reached 24% of sales, supporting...
25 Jan 2022
Lonza Obtains Order Preventing Infringement of Its Patents Covering the Cocoon® Platform
On January 21, 2022, a United States federal district court entered a preliminary injunction preventing infringement of Lonza’s patents related to its innovative Cocoon®...
1 2 3 4 ... 25 >